CD44 Link Region Peptide Modulates FAK Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective compounds to treat and diagnose conditions characterized by aberrant cell migration and invasion, particularly in cancer metastasis and inflammatory processes, where CD44 plays a crucial role.
Innovation Solution
Development of peptides, such as Å6 polypeptides and their variants, that bind to CD44, modulating the FAK signal transduction pathway to treat and diagnose aberrant cell migration and invasion by inhibiting chemotaxis and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD44 is targeted to treat aberrant cell migration and invasion, then therapeutic efficacy is improved, but the complexity of developing and validating the treatment increases
Solution Approach 1:
The patent extracts the critical functional domain of CD44 (the Link region, amino acids 120-127) to create a simplified peptide compound (SEQ ID NO:3) that retains the ability to modulate FAK signaling and inhibit cell migration. This extraction approach reduces the complexity of the therapeutic agent while maintaining efficacy, as the peptide is smaller and easier to produce and validate compared to full-length CD44 antibodies or monoclonal antibodies.
2Reliability
If CD44 binding compounds are developed for cancer metastasis treatment, then patient outcomes improve, but the cost and time for clinical development increase
Solution Approach 1:
The patent employs a small peptide compound (SEQ ID NO:3) that is inexpensive to produce and rapidly testable in preclinical models. This disposable-like approach allows for quick iteration and validation before clinical trials, significantly reducing the time and cost compared to developing complex monoclonal antibodies or antibody-drug conjugates that require extensive characterization and validation.
3Object-generated harmful factors
If FAK signal transduction pathway is modulated, then cell migration and invasion are inhibited, but the specificity and selectivity of the modulation becomes more difficult to achieve
Solution Approach 1:
The patent targets a specific local region of CD44 (amino acids 120-127, the Link region) that is critical for FAK signaling activation. By focusing the peptide (SEQ ID NO:3) on this specific local domain, the modulation of FAK signaling becomes more specific and controllable, as the peptide directly interacts with the precise structural element responsible for pathway activation, rather than broadly affecting all CD44 functions.
Data Source
AI summary
A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.